Press Release

Category Added in a WPeMatico Campaign

Business Wire2 weeks ago

PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm

LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More »
Business Wire2 weeks ago

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More »
Business Wire2 weeks ago

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More »
Business Wire2 weeks ago

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with…
Read More »
Business Wire2 weeks ago

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage…
Read More »
Cision PR Newswire2 weeks ago
0

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients Rezpegaldesleukin proof-of-concept…
Read More »
Business Wire2 weeks ago

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through…
Read More »
Business Wire2 weeks ago

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its…
Read More »
Business Wire2 weeks ago

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG…
Read More »
Cision PR Newswire2 weeks ago
0

Record Your Passion: TORRAS Partners with Portugal Football for the Season Ahead

NEW YORK, March 28, 2026 /PRNewswire/ — In 2026, Portugal will begin a World Cup journey with special significance. After…
Read More »

Previous page Next page